GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS
Revenue$8.2 billion+16% YoY
EPS$1.94
Outlookraisedguidance
Earnings release · GILD
GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS
Gilead Sciences, Inc. · Filed · SEC Form 8-K, Item 2.02
Revenue
$7.6 billion
+10% vs a year ago
EPS
$1.56
not detected
Guidance
raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue grew 10% year on year to $7.6 billion, and EPS was $1.56. The company lifted its guidance, which is usually read as management's view of coming periods improving.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
$7.6 billion +10% vs a year ago
…Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion.…
EPS
$1.56
…share (“EPS”) was $(8.45) in the second quarter 2026 compared to $1.56 in the same period in 2025.…
Guidance
Guidance raised
…ntinued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer.…
Trend: last 2 reports
All releases →Other releases from Gilead Sciences, Inc.
All →
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.